Cargando…

Lifetime risks, loss of life expectancy, and health care expenditures for 19 types of cancer in Taiwan

BACKGROUND: The mortality rates for different cancers are no longer an efficient tool for making national policy. The purpose of this study were to quantify the lifetime risks, life expectancies (LEs) after diagnosis, expected years of life lost (EYLL), and lifetime health care expenditures for 19 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Tzu-Yi, Chung, Chia-Hua, Lin, Chia-Ni, Hwang, Jing-Shiang, Wang, Jung-Der
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973634/
https://www.ncbi.nlm.nih.gov/pubmed/29872347
http://dx.doi.org/10.2147/CLEP.S155601
_version_ 1783326672352706560
author Wu, Tzu-Yi
Chung, Chia-Hua
Lin, Chia-Ni
Hwang, Jing-Shiang
Wang, Jung-Der
author_facet Wu, Tzu-Yi
Chung, Chia-Hua
Lin, Chia-Ni
Hwang, Jing-Shiang
Wang, Jung-Der
author_sort Wu, Tzu-Yi
collection PubMed
description BACKGROUND: The mortality rates for different cancers are no longer an efficient tool for making national policy. The purpose of this study were to quantify the lifetime risks, life expectancies (LEs) after diagnosis, expected years of life lost (EYLL), and lifetime health care expenditures for 19 major cancers in Taiwan. METHODS: A total of 831,314 patients with 19 pathologically proven cancers were abstracted from the Taiwan Cancer Registry from 1998 to 2012. They were linked to the National Mortality Registry (1998–2014) and National Health Insurance reimbursement database (1998–2013) for survival and health care costs. We estimated the cumulative incidence rate for ages 0–79 years and the lifetime survival function for patients with different cancer sites. The EYLL was calculated by subtracting the LE of each cancer cohort from that of the age- and sex-matched referents simulated from national life tables. The estimated lifetime cost was calculated by adding up the product of survival probability and mean cost at the corresponding duration-to-date after adjustment for the inflation to the year of 2013. RESULTS: There were 5 cancers with a lifetime risk exceeding 4%: colorectal, liver, lung, and prostate in males, and breast and colorectal in females. Cancers with EYLL of >10 years were: esophageal, intrahepatic bile ducts, liver, pancreas, oral, nasopharyngeal, leukemia, lung, and gallbladder, extrahepatic bile ducts and biliary tract in males, and intrahepatic bile ducts, pancreas, nasopharyngeal, lung, esophageal, leukemia, liver, gallbladder, extrahepatic bile ducts and biliary tract, ovary, and stomach in females. Cancers with lifetime health care expenditures exceeding US$50,000 to the National Health Insurance were as follows: leukemia, kidney, testis, renal pelvis and ureter in males, and renal pelvis and ureter, leukemia, breast, urinary bladder, kidney, ovary, and nasopharyngeal in females. All these impacts should be considered in health policy decisions. CONCLUSION: The impacts of cancer in Taiwan are very large. Future studies must consider both quality of life and the entire impact from societal perspectives.
format Online
Article
Text
id pubmed-5973634
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59736342018-06-05 Lifetime risks, loss of life expectancy, and health care expenditures for 19 types of cancer in Taiwan Wu, Tzu-Yi Chung, Chia-Hua Lin, Chia-Ni Hwang, Jing-Shiang Wang, Jung-Der Clin Epidemiol Original Research BACKGROUND: The mortality rates for different cancers are no longer an efficient tool for making national policy. The purpose of this study were to quantify the lifetime risks, life expectancies (LEs) after diagnosis, expected years of life lost (EYLL), and lifetime health care expenditures for 19 major cancers in Taiwan. METHODS: A total of 831,314 patients with 19 pathologically proven cancers were abstracted from the Taiwan Cancer Registry from 1998 to 2012. They were linked to the National Mortality Registry (1998–2014) and National Health Insurance reimbursement database (1998–2013) for survival and health care costs. We estimated the cumulative incidence rate for ages 0–79 years and the lifetime survival function for patients with different cancer sites. The EYLL was calculated by subtracting the LE of each cancer cohort from that of the age- and sex-matched referents simulated from national life tables. The estimated lifetime cost was calculated by adding up the product of survival probability and mean cost at the corresponding duration-to-date after adjustment for the inflation to the year of 2013. RESULTS: There were 5 cancers with a lifetime risk exceeding 4%: colorectal, liver, lung, and prostate in males, and breast and colorectal in females. Cancers with EYLL of >10 years were: esophageal, intrahepatic bile ducts, liver, pancreas, oral, nasopharyngeal, leukemia, lung, and gallbladder, extrahepatic bile ducts and biliary tract in males, and intrahepatic bile ducts, pancreas, nasopharyngeal, lung, esophageal, leukemia, liver, gallbladder, extrahepatic bile ducts and biliary tract, ovary, and stomach in females. Cancers with lifetime health care expenditures exceeding US$50,000 to the National Health Insurance were as follows: leukemia, kidney, testis, renal pelvis and ureter in males, and renal pelvis and ureter, leukemia, breast, urinary bladder, kidney, ovary, and nasopharyngeal in females. All these impacts should be considered in health policy decisions. CONCLUSION: The impacts of cancer in Taiwan are very large. Future studies must consider both quality of life and the entire impact from societal perspectives. Dove Medical Press 2018-05-25 /pmc/articles/PMC5973634/ /pubmed/29872347 http://dx.doi.org/10.2147/CLEP.S155601 Text en © 2018 Wu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Wu, Tzu-Yi
Chung, Chia-Hua
Lin, Chia-Ni
Hwang, Jing-Shiang
Wang, Jung-Der
Lifetime risks, loss of life expectancy, and health care expenditures for 19 types of cancer in Taiwan
title Lifetime risks, loss of life expectancy, and health care expenditures for 19 types of cancer in Taiwan
title_full Lifetime risks, loss of life expectancy, and health care expenditures for 19 types of cancer in Taiwan
title_fullStr Lifetime risks, loss of life expectancy, and health care expenditures for 19 types of cancer in Taiwan
title_full_unstemmed Lifetime risks, loss of life expectancy, and health care expenditures for 19 types of cancer in Taiwan
title_short Lifetime risks, loss of life expectancy, and health care expenditures for 19 types of cancer in Taiwan
title_sort lifetime risks, loss of life expectancy, and health care expenditures for 19 types of cancer in taiwan
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973634/
https://www.ncbi.nlm.nih.gov/pubmed/29872347
http://dx.doi.org/10.2147/CLEP.S155601
work_keys_str_mv AT wutzuyi lifetimeriskslossoflifeexpectancyandhealthcareexpendituresfor19typesofcancerintaiwan
AT chungchiahua lifetimeriskslossoflifeexpectancyandhealthcareexpendituresfor19typesofcancerintaiwan
AT linchiani lifetimeriskslossoflifeexpectancyandhealthcareexpendituresfor19typesofcancerintaiwan
AT hwangjingshiang lifetimeriskslossoflifeexpectancyandhealthcareexpendituresfor19typesofcancerintaiwan
AT wangjungder lifetimeriskslossoflifeexpectancyandhealthcareexpendituresfor19typesofcancerintaiwan